GLP-1 medications can feel almost mysterious from the outside: people eat less without white-knuckling it, and cravings quiet down. But there's nothing mysterious about the biology. These medications work by extending a signal your own body already sends after every meal.
The hormone you already make
GLP-1 (glucagon-like peptide-1) is a hormone your gut releases when you eat. It tells your brain you're satisfied, slows how fast your stomach empties, and helps your body manage blood sugar. The catch: natural GLP-1 breaks down within minutes.
Semaglutide and tirzepatide are built to mimic that hormone and last far longer, days rather than minutes. So the “I'm full” signal stays switched on instead of fading right after a meal.
Four things it does
- Reduces appetite by acting on the appetite centers of the brain, so many people feel satisfied with less.
- Slows digestion, which can keep you fuller for longer after eating.
- Steadies blood sugar in a glucose-dependent way, supporting more stable energy between meals for some people.
- Quiets cravings for many patients: a common reported experience, not a separate registered indication.
These medications don't override your biology; they work with it, extending a signal you already produce.
Why tirzepatide adds a second signal
Semaglutide targets one receptor: GLP-1. Tirzepatide targets two: GLP-1 and a second gut hormone called GIP. Dual-pathway therapy is often considered when a provider and patient prefer that mechanism after reviewing history and goals. Both are titrated gradually; brand trial averages are not a personal timeline.
The “food noise” effect
One of the most common things patients describe isn't on any lab report: the volume knob on food gets turned down. Decisions that used to take willpower start to feel automatic. That's the appetite and reward signaling settling, not a stimulant and not magic.
The bottom line
Medication is one part of the picture; a licensed provider tuning the dose to how you respond is what turns the mechanism into results. In the STEP 1 trial, adults on brand semaglutide 2.4 mg weekly lost a mean of 14.9% of body weight over 68 weeks versus 2.4% with placebo. Those averages describe the studied brand regimen and population, not compounded preparations. Individual results may vary.
